

Instructions to Grant Applicants

The RDH12 Fund for Sight is a registered 501(c)(3) organization founded by parents of children diagnosed with Leber's Congenital Amaurosis, or LCA, due to mutations in the *Retinol Dehydrogenase 12 (RDH12)* gene. The RDH12 Fund for Sight seeks to support work that directly relates to the development of a therapeutic for the treatment of LCA due to *RDH12* mutations. The RDH12 Fund for Sight will consider all applications that meet these criteria.

Proposal Format

A new grant proposal for funding from the RDH12 Fund for Sight should consist of the following sections.

<u>Cover Page</u> – Should include the title of grant application, the name of the principal investigator, affiliation and contact information of the principal investigator, and institutional signature. Should not exceed 1 page in length.

<u>Proposal Body</u> – Should describe the proposed work. Should not exceed 5 pages in length and must include the following subsections:

Scientific Abstract Layman's Abstract Specific Aims Description of Proposed Work Preliminary Data (if any)

<u>Deliverables and Timeline</u> – This section is only required if seeking funding across multiple years. Must include description of specific goals that if reached would trigger the next year of funding. Should not exceed 1 page in length.

<u>Budget</u> – Breakdown of how requested funds will be spent in support of proposed work. Should not exceed 1 page in length.

<u>Key Personnel</u> – List of personnel that will support the proposed research, title of individual, and description of the role of the individual in the project. Should not exceed 1 page in length.

NIH Biosketch of Key Personnel - No page limit

<u>References</u> – No page limit

Requirements of Investigators upon Award Receipt

In accepting funds from the RDH12 Fund for Sight, the investigator agrees to provide the RDH12 Fund for Sight with a written progress report on a quarterly basis. Publications resulting from work generated with funding by the RDH12 Fund for Sight must acknowledge the support of the RDH12 Fund for Sight. The RDH12 Fund for Sight must actively publicize the work that it funds in order keep its many supporters engaged in the effort and mission of the Fund. The RDH12 Fund for Sight will consult with the investigator before disseminating updated information of funded work to its supporters to ensure that no proprietary information is shared prematurely.

Funding Cycles and Timing of Awards

The RDH12 Fund for Sight maintains an open solicitation for new applications. The number of awards depends on currently available funds and existing funding commitments. Upon receipt of a new application for funding, the RDH12 Fund for Sight will provide a decision on the application within 2 weeks. If the application is successful and funds are available, a transfer of funds will be made within 2 weeks of the funding decision.

Overhead Policy

The RDH12 Fund for Sight has limited resources available to support LCA-RDH12 research and seeks to maximize the value of every contribution it receives for the development of a cure for LCA-RDH12. Therefore, it is the policy of the RDH12 Fund for Sight to not award indirect costs in excess of 5% of the total award.